Eight-year-old Emily is terminally ill. Her parents appeal to Julia Schemmel, chairwoman of a small pharmaceutical company researching her illness, to request early access to an unapproved drug. However, this poses significant risks for the company as it could potentially halt the product's development, preventing patients in the future from receiving the benefits of the medication.
Eine riskante Entscheidung
Eight-year-old Emily is terminally ill. Her desperate parents reach out to Julia Schemmel, the head of a small pharmaceutical company conducting research in this area, to request early access to an experimental drug not yet available on the market. However, the stakes are high for the company; granting this request risks severe consequences, including potentially halting the drug's development altogether, which would mean that no one could benefit from the treatment in the future.
